Showing results (61-70 of 102) with videos related to
Sort By:
Pageof 11
Cancer|February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Journal of Neuro-Oncology|October 12, 2011
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastomaDavid A Reardon, Annick Desjardins, Katherine B Peters, et al.Neuro-Oncology|August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaSith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.Journal of Neuro-Oncology|May 6, 2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.Journal of Neuro-Oncology|October 15, 2011
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patientsDavid A Reardon, James E Herndon, Katherine Peters, et al.Neuro-Oncology|August 30, 2008
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastomaSridharan Gururangan, Jeanne Krauser, Melody A Watral, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasAnnick Desjardins, David A Reardon, James E Herndon, et al.Journal of Neuro-Oncology|March 13, 2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.Pageof 11